Baricitinib is a JAK1–2 inhibitor recently approved in Europe and Japan for the treatment of moderate-to-severe atopic dermatitis in adult patients at doses of 2 and 4 mg daily. The aim of this article is to discuss the safety profile of baricitinib in atopic dermatitis using data from clinical trials and the supporting literature, with a focus on infectious adverse events. An integrated analysis of safety data from eight clinical trials described infections as the most frequent treatment-emergent adverse events, mainly of mild-to-moderate severity, notably upper respiratory tract infections and herpes simplex exacerbations. Real-world data are still limited and will contribute to precisely profile the patients that might benefit from this treatment.

Antonelli, F., Malvaso, D., Caldarola, G., De Simone, C., Peris, K., Chiricozzi, A., Infectious adverse events in patients with atopic dermatitis treated with baricitinib, <<IMMUNOTHERAPY>>, 2023; 15 (18): 1521-1529. [doi:10.2217/imt-2023-0078] [https://hdl.handle.net/10807/261987]

Infectious adverse events in patients with atopic dermatitis treated with baricitinib

Antonelli, Flaminia;Malvaso, Dalma;Caldarola, Giacomo;De Simone, Clara;Peris, Ketty;Chiricozzi, Andrea
2023

Abstract

Baricitinib is a JAK1–2 inhibitor recently approved in Europe and Japan for the treatment of moderate-to-severe atopic dermatitis in adult patients at doses of 2 and 4 mg daily. The aim of this article is to discuss the safety profile of baricitinib in atopic dermatitis using data from clinical trials and the supporting literature, with a focus on infectious adverse events. An integrated analysis of safety data from eight clinical trials described infections as the most frequent treatment-emergent adverse events, mainly of mild-to-moderate severity, notably upper respiratory tract infections and herpes simplex exacerbations. Real-world data are still limited and will contribute to precisely profile the patients that might benefit from this treatment.
2023
Inglese
Antonelli, F., Malvaso, D., Caldarola, G., De Simone, C., Peris, K., Chiricozzi, A., Infectious adverse events in patients with atopic dermatitis treated with baricitinib, <<IMMUNOTHERAPY>>, 2023; 15 (18): 1521-1529. [doi:10.2217/imt-2023-0078] [https://hdl.handle.net/10807/261987]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/261987
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 3
social impact